Redhill Biopharma Ltd

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused primarily on gastrointestinal and infectious diseases. It develops and commercializes Talicia for H. pylori infection in adults and Aemcolo for travelers' diarrhea in adults, and also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. Its pipeline includes five therapeutic candidates in clinical development: opaganib, Rebyota, RHB-107 (upamostat), RHB-104, RHB-102 (Bekinda), and RHB-204. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.